Journals / Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi / 2023 / Cilt: 43 Sayı: 4

Evaluation of Neopterin Levels and Kynurenine Pathway in Acute Coronary Syndrome Patients

Neopterin Düzeylerinin ve Kinürenin Yolağının Akut Koroner Sendrom Hastalarında Değerlendirilmesi

Pages
340–351
Publication Date
2023-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Determination and use of neopterin levels and kynurenine pathway parameters as biomarkers in acute coronary syndrome patients are meaningful and valuable.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The leading cause of coronary artery disease is coronary atherosclerosis.
📊
Key Findings & Data:In addition to the release of neopterin in cellular immune activation, indolamine 2,3-dioxygenase (IDO), which catalyzes the rate limiting step in tryptophan degradation, is also induced.
💡
Conclusion & Impact:Determination and use of neopterin levels and kynurenine pathway parameters as biomarkers in acute coronary syndrome patients are meaningful and valuable.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Neopterin · İDO · triptofan

Abstract

The leading cause of coronary artery disease is coronary atherosclerosis. Intracoronary thrombus caused by rupture of atherosclerotic plaque is the main cause of acute coronary syndrome. It has been shown in various studies that tear-sensitive plaques contain more macrophages and T lymphocytes. Neopterin is an important biomarker of cellular immune response. It is considered an important biomarker of early diagnosis and prognosis in a wide variety of pathologies, including inflammation, infections and malignancies. In addition to the release of neopterin in cellular immune activation, indolamine 2,3-dioxygenase (IDO), which catalyzes the rate limiting step in tryptophan degradation, is also induced. It has been reported that the IDO activity, shown by kynurenine (Kyn) to tryptophan (Trp) ratio, can be used as an important indicator in the regulation of cellular immunity, supported by immune variables. In this review, it is aimed to evaluate the possible changes in the diagnosis of coronary artery disease (CAD), mortality and morbidity determination of biochemical indicators such as neopterin, C-reactive protein (CRP), IDO in patients with acute coronary syndrome that develop angiographically on the basis of atherosclerosis. Determination and use of neopterin levels and kynurenine pathway parameters as biomarkers in acute coronary syndrome patients are meaningful and valuable.

Özet

Neopterin Düzeylerinin ve Kinürenin Yolağının Akut Koroner Sendrom Hastalarında Değerlendirilmesi Koroner arter hastalığının en önemli nedeni koroner aterosklerozdur. Aterosklerotik plağın yırtılması ile oluşan intrakoroner trombüs ise akut koroner sendomun temel nedenidir. Yırtılmaya hassas plakların daha fazla sayıda maktofaj ve T lenfosit içerdiği çeşitli çalışmalarda gösterilmiştir. Neopterin hücresel immün yanıtın önemli bir biyogöstergesidir. İnflamasyon, çeşitli enfeksiyonlar ve maligniteler de dahil olmak üzere çok çeşitli patolojilerde erken tanı ve prognoz için önemli bir biyomarkör olarak kabul edilir. Hücresel immün aktivasyonda neopterin salınımına ilave olarak triptofan yıkımında hız kısıtlayıcı basamağı katalizleyen indolamin 2,3-dioksijenaz (İDO) enzimi de aynı anda indüklenir. Kinürenin (Kyn) in triptofan (Trp) ’a oranlanmasıyla ifade edilebilien İDO aktivitesinin, immün değişkenlerle desteklenerek hücresel immünitenin düzenlenmesinde önemli bir gösterge olarak kullanılabileceği rapor edilmiştir. Bu derleme makalesinde, anjiyografik olarak ateroskleroz zemininde gelişen akut koroner sendrom (AKS) hastalarında, neopterin, C reaktif protein (CRP), İDO gibi biyokimyasal göstergelerin koroner arter hastalığı (KAH) tanısı, mortalite ve morbidite süreçlerindeki olası değişimlerin değerlendirilmesi hedeflenmiştir. Akut koroner sendrom hastalarında, neopterin düzeyleri ile kinürenin yolağı parametlerinin belirlenmesi ve biyomarkör olarak kullanılmaları anlamlı ve değerlidir.

🔖

Cite This Article

KEMBER, İ., GİRGİN, G., BAYDAR, T. (2023). Evaluation of Neopterin Levels and Kynurenine Pathway in Acute Coronary Syndrome Patients. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 43 Sayı: 4, 340–351. https://ajindex.com/articles/1020984

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Sulo G, Vollset SE, Nygard O, Midttun O, Ueland PM, Eussen SJPM, et al. Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. International Journal of Cardiology. 2013, 168:1435-1440. DOI: 10.1016/j.ijcard.2012.12.090 2. Sugioka K, Naruko T, Matsumura Y, Shirai N, Hozumi T, Yoshiyama M, et al. Neopterin and atherosclerotic plaque instability in coronary and carotid arteries. Journal of Atherosclerosis and Thrombosis. 2010, 17(11):1115-1121. DOI: 10.5551/ jat.4606 3. Polyzos KA, Ketelhuth DF. The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease. An emerging field. Hamostaseologie. 2015, 35:128–136. DOI: 10.5482/HAMO-14-10-0052 4. Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation associated production of neopterin derivatives in humans. Inflammation Research. 2003, 52:313-321. DOI: 10.1007/s00011-003-1181-9 5. Eisenhut M. Neopterin in diagnosis and monitoring of infectious diseases. Journal of Biomarkers. 2013, 2013:196432. DOI: 10.1155/2013/196432 6. Soliman H, Mediavilla-Varela M, Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer Journal. 2010, 16:354- 359. DOI: 10.1097/PPO.0b013e3181eb3343 7. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clinica Chimica Acta. 2006, 364:82-90. DOI: 10.1016/j. cca.2005.06.013 8. King NJ, Thomas SR. Molecules in focus: Indoleamine 2,3-dioxygenase. The International Journal Biochemistry and Cell Biolology. 2007, 39:2167–2172. DOI: 10.1016/j.biocel. 2007.01.004 9. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood. 2009, 113:2394-2401. DOI: 10.1182/blood-2008-07-144485 10. Fox KAA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). European Heart Journal. 2002, 23:1177-1189 DOI: 10.1053/euhj.2001.3081 11. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Global Heart. 2012, 7(4):275-95. 126:2020-2035. DOI: 10.1016/j.gheart.2012.08.001 12. WHO reveals leading causes of death and disability worldwide: 2000-2019. Erişim Adresi: https://www.who.int/news/ item/09-12-2020-who-reveals-leading-